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The w-conotoxins, a class of Ca2+ channel antagonists 
from fish-hunting marine snails, have recently been 
described (Olivera, B. M., McIntosh, J. M., Zeikus, R., 
Gray, W. R., Varga, J., Rivier, J., de Santos, V., and 
Cruz, L. J. (1985) Science, 230, 1338-1343). One of 
these peptide neurotoxins, w-conotoxin GVIA, was ra-
diolabeled witb iodine, and the 125I-Iabeled toxin was 
shown to bind specifically to high affinity sites on chick 
brain synaptosomes. The toxin-receptor complex was 
extremely stable; addition of an excess of unlabeled 
toxin did not cause significant displacement of the 
labeled toxin after 2 h. 
Binding competition data suggest that w-conotoxin 
defines a new high affinity receptor site affecting volt-
age-activated Ca2+ channels, distinct from both the 
verapamil and dihydropyridine target sites. 
Voltage-activated calcium channels are ubiquitously found 
in nerve and muscle. These ion channels are believed to 
transduce electrical signals in excitable tissues into biochem-
ical changes (1-4). A prominent treatise on ion channels 
describes the importance of Ca2+ channels succinctly, "with-
out calcium channels our nervous system would have no 
outputs" (1). 
Neuronal Ca2+ channels have not been extensively charac-
terized at the molecular level, compared to acetylcholine 
receptors and Na2+ channels. To investigate the latter mole-
cules, the use of drugs and toxins which affect the activity of 
the channels has been indispensable. The development of a-
bungarotoxin which binds the acetylcholine receptor with 
high affinity was the key to a biochemical characterization of 
this receptor (5). The availability of guanidinium, alkaloid, 
and peptide toxins which bind to different sites on the Na+ 
channel have greatly facilitated the dissection of this channel 
(6). 
The agents currently in widest use for studying calcium 
channels are the dihydropyridines (i.e. nitrendipene, nifedi-
pine, and related compounds) and anti-arrhythmic drugs such 
as verapamil; these agents define at least two distinct, though 
coupled, binding sites which affect Ca2+ channel activity (2-
4, 7,8). Recently, we reported the isolation and purification 
of a new class of presynaptic toxins, the w-conotoxins from 
the venom of fish-hunting snails (9, 10). Electrophysiological 
work on one of these toxins, w-conotoxin GVIA, has shown 
that the toxin blocks voltage-activated calcium channels at 
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the frog neuromuscular junction, and, indeed, blocks all frog 
synapses tested (11). Thus, w-conotoxins are very promising 
tools for studying voltage-activated calcium channels at syn-
apses. 
In this paper, we demonstrate specific high affinity binding 
of w-conotoxin GVIA to synaptosomal and membrane prepa-
rations from chick brain. We also provide evidence that w-
conotoxins define a new class of target sites which affect Ca2+ 
channels, distinct from both dihydropyridine- and verapamil-
binding sites. 
EXPERIMENTAL PROCEDURES 
Materials-w-Conotoxin GVIA (W-CgTx') was purified as described 
by Olivera et al. (9). [5-methyPHjnitrendipine was obtained from 
New England Nuclear. All other calcium antagonists and the protease 
inhibitors were purchased from Sigma. Iodogen was obtained from 
Pierce Chemical Co. 
Membrane Preparations-Membrane fractions enriched in T tu-
bules were prepared according to the method of Glossman et al. (12) 
from the hind leg muscle of Northern grass frogs, Rana pipiens. 
Synaptosomes were prepared from the brain of frogs and 19-20-
day-old chick embryo essentially as described by Catterall et al. (13) 
except that all sucrose solutions were buffered with 5 mM HEPES/ 
Tris, pH 7.4, and contained the following protease inhibitors: 1 /tM 
pepstatin A, 2 /tM leupeptin, 1 mM phenylmethylsulfonyl fluoride, 
and 1 mM 1,10-phenanthroline. For chick brain, the stepwise gradient 
was modified such that the bottom layer contained 1.3 M instead of 
1.2 M sucrose. All fractions were pelleted, resuspended in 0.32 M 
sucrose, 5 mM HEPES/Tris, pH 7.4, containing protease inhibitors, 
and stored either on ice or in the deep freezer. For some experiments, 
the heavy synaptosome fraction of the 1.0-1.3 M sucrose interface 
was lysed and the membranes fractionated as described by Catterall 
et al. (13). 
Iodination of w-CgTx-The toxin was iodinated according to the 
method of Fraker and Speck (14) using ['25I1NaI (0.20 mCi/nmol) as 
label and rodogen as a solid phase reagent. The iodinated material 
was applied on a 3-ml Sephadex G-lO column and eluted with 5% 
acetic acid. The radioactive peak which eluted close to the void volume 
was pooled and purified by high pressure liquid chromatography using 
a VYDAC C18 column (0.46 x 25 cm; 5-/tm particle, not end capped) 
at a flow rate of 1 ml/min. A gradienf was applied using Solvent A, 
0.1 % trifluoroacetic acid, and Solvent B, 0.1 % trifluoroacetic acid in 
60% (v/v) acetonitrile (15). A representative chromatogram is shown 
in Fig. 2. The biological activity of the radiolabeled peaks was deter-
mined as described previously (9). The two major peaks of iodinated 
derivatives were biologically active. In two independent determina-
tions/sample, iodinated conotoxin GVIA gave specific activities of 14 
and 27 units/nmol for the early and 22 and 60 units/nmol for the 
later eluting peaks, respectively. The specific activity of unmodified 
toxin was 70 units/nmol. One unit of w-CgTx produces detectable 
symptoms in 30 min after intracranial injection of a 16-19-day-old 
mouse. For the 125I-labeled w-CgTx preparation used in most of the 
binding assays described below, the two peaks were pooled, dried, and 
taken up on 0.32 M sucrose, 5 mM HEPES/Tris, pH 7.4, containing 
0.2 mg/ml lysozyme. In the experiments in Fig. 3 and Table I, only 
1 The abbreviations used are: w-CgTx, w-conotoxin GVIA; HEPES, 
4-(2-hydroxyethyl) -l-piperazineethanesulfonic acid. 
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the larger later eluting iodinated peak was used. The 1251-labeled 
preparation had specific activities in the range of 1- 4 X 108 cpm/ 
nmo!. 
Binding Assays-The measurement of [3Hjnitrendipine binding to 
membrane preparation from frog brain and muscle was done as 
described by Curtis and Catterall (16). 
For measuring the binding of 1251-labeled w-CgTx to brain synap-
tosomes and T tubule preparations, the assay mix (200 JL!) contained 
the following; 30-100 I1g of membrane protein, 125I-Iabeled w-CgTx, 
0.01 mg/mllysozyme, 0.32 M sucrose, 5 mM HEPES/Tris, pH 7.4. To 
measure nonspecific binding, 0.25 11M cold w-CgTx was preincubated 
for 30 min with the membrane preparations before ' 251-labeled w-
CgTx was added. The mixture was then incubated at room tempera-
ture for 30 min-l h and diluted with 2-3 ml of ice-cold wash medium 
containing 160 mM choline chloride, 5 mM HEPES/Tris, pH 7.4, 1.5 
mM CaCh, and 1 mg/ml bovine serum albumin. Membranes were 
collected on glass fiber ftIters (Whatman GF/C) under vacuum and 
washed 3 times with 2 ml of wash medium. Radioactivity of filters 
and sometimes of ftItrates was determined. 
RESULTS 
w-Conotoxin Does Not Compete with Nitrendipine for Bind-
ing to T Tubule Skeletal Muscle Sites-One of the richest 
sources of dihydropyridine-binding sites are T tubule prepa-
rations from skeletal muscles (12, 17); the nitrendipine-bind-
ing site has been purified from this tissue (18, 19). We have 
investigated w-conotoxin competition for the high affinity 
dihydropyridine-binding sites of skeletal muscle. 
The binding of [3H]nitrendipine to the high affinity dihy-
dropyridine sites of frog skeletal muscle is shown in Fig. 1. 
These data on nitrendipine binding are consistent with pre-
vious reports in the literature. These results demonstrate that 
while nifedipine competes effectively with the labeled nitren-
dipine for binding, the addition of purified w-conotoxin does 
not detectably reduce the binding of [3H]nitrendipine, even 
at lOOO-fold excess. We conclude that w-conotoxin does not 
compete with [3H]nitrendipine for the high affinity dihydro-
pyridine T tubule sites. 
Specific Binding of w-Conotoxin to Synaptosomal Prepara-
tions-In order to examine the binding of w-conotoxin di-
rectly, it is necessary to have radioactive biologically active 
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FIG. 1. The binding of [3H]nitrendipine to membrane prep-
aration from frog skeletal muscle. A membrane preparation 
enriched in T tubules was prepared, and the binding assay was done 
as described under "Experimental Procedures." The reaction mixture 
(0.2 m!) contained 1-5 nM [3Hjnitrendipine (81.3 /LCi/nmo!), 36.7 I1g 
of membrane protein, 94 mM choline chloride, 4 mM glucose, 50 mM 
KCI, 1.5 mM CaCl2 and 78 mM HEPES/Tris, pH 7.4. Total binding 
is represented by •. Nonspecific binding was estimated by preincu-
bating the membrane preparation with 111M nifedipine (Nfdp) for 30 
min at O·C before adding [3Hjnitrendipine (x). Membrane prepara-
tions were also preincubated with 10 11M w-CgTx (e). Incubation with 
[3Hjnitrendipine was carried out on ice for 1 h. 
ried out as described under "Experimental Procedures." A 
high pressure liquid chromatography analysis of the iodinated 
toxin is shown in Fig. 2. The biological activity of the various 
peaks was tested; the two major peaks (indicated by shading) 
which were radioactively labeled were biologically active (see 
"Experimenta1 Procedures"). The toxin preparation used in 
most experiments comprised a pool of the two peaks indicated 
in the figure. 
The radiolabeled toxin was used for binding assays as 
described under "Experimental Procedures." A number of 
tissues from frog and chick were tested in a preliminary 
survey. It was found that the frog skeletal muscle preparation 
used for the [3H]nitrendipine-binding studies gave marginal 
levels of binding. In contrast, crude frog and chick brain 
preparations gave easily detectable levels of specific binding. 
Because of the greater accessibility of chick brain, this tissue 
was used in all subsequent experiments. 
Chick brain synaptosomal membranes were purified (see 
"Experimenta1 Procedures"). Iodinated w-conotoxin was 
added to synaptosomal membranes (Figs. 3 and 4), and a 
saturable binding component was detected which meets all 
criteria for specific binding. The amount of binding at satu-
ration is proportional to the amount of membrane preparation 
provided (Table I). These results demonstrate that a high 
affinity w-conotoxin-binding site can be assayed by the 
method used. In the experiments in Figs. 3 and 4, apparent 
half-saturation of the receptor is achieved at subnanomolar 
concentrations of toxin. However, equilibrium has not been 












FIG. 2. Chromatographic purification of 125I-w-conotoxin 
GVlA on VYDAC CIS analytical column. Solvent A, 0.1% tri-
fluoroacetic acid; Solvent B, 0.1% trifluoacetic acid in 60% (v/v) 
acetonitrile. Iodinated derivatives of GVIA were eluted at 1 ml/min 
with a linear gradient expressed as a percentage of Solvent B achieved 
at times given in parentheses (min); 10(0)/10(2)/50(42). For the 
chromatogram shown, 20 nmol of GVIA were iodinated using 20 nmol 
of ['25IjNaI. Unmodified w-conotoxin GVIA is indicated by the arrow. 
The shaded peaks are iodinated derivatives which retained significant 
biological activity and which were used for the binding assays de-
scribed in this report. 
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6232 Calcium Channel Antagonists 
TABLE I 
Proportionality of toxin binding to synaptosomal protein 
concentration 
Binding assays were carried out as described under "Experimental 
Procedures" using the same chick brain synaptosome and 125I-labeled 
w-CgTx preparations as in Fig. 3. The concentrations of toxin used 
were saturating; the protein concentration was varied as shown. 
Nonspecific binding has been corrected for as described in the legend 






















1201 -labeled Toxin Protein 
w-CgTx bound 
nM fmol pmol/mg 
2.0 49 2.1 
4.0 41 1.7 
2.0 79 1.7 
4.0 92 1.9 
2.0 160 1.7 
4.0 170 1.8 
o _____ §-----------o /' 
o 
o 
2 4 6 8 
r251-WCgTx].nM 
FIG. 3. The binding of 125I_Iabeled w-CgTx to chick brain 
synaptosomes. Synaptosomes were prepared and the binding assay 
done as described under "Experimental Procedures." Upper panel, 
the reaction mixture (e) contained various concentrations of 1251_ 
labeled w-CgTx, 94.1 p.g of membrane protein, 0.01 mg/mllysozyme, 
0.32 M sucrose, 5 mM HEPES/Tris, pH 7.4, in a total volume of 90.2 
!ll. Nonspecific binding (0) was determined in parallel reactions by 
preincubating synaptosomal preparations with 0.25 !lM unlabeled w-
CgTx for 30 min on ice before the addition of radiolabeled toxin. 
Incubation with 125I-labeled w-CgTx was done for 30 min at room 
temperature. The ' 25I-labeled w-CgTx used (peak eluting at 28 min in 
Fig. 2) had a specific activity of 1.57 x 108 cpm/nmol. Lower panel, 
the same data as in the upper panel replotted after subtraction of 
nonspecific binding. 
sociation of toxin for receptor within the assay time frame 
(see below). 
Competition of Nifedipine, Verapamil, and w-Conotoxin for 
Binding to Brain Synaptosomes-Two classes of pharmaco-
logically active agents have been used to study voltage-acti-
vated Ca2+ channels, the anti-arrhythmic drugs (typified by 
verapamil) and the dihydropyridines. We have examined 
whether verapamil will compete with w-conotoxin binding 
using brain synaptosomal preparations (see Fig. 4). The pres-
ence of an excess of verapamil (1 mM) does not affect 1251_ 
labeled w-conotoxin binding to the high affinity site. We 
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FIG. 4. Effect of verapamil on 125I_Iabeled w-CgTx binding. 
The synaptic membrane preparation from chick brain and the assay 
procedure are as described under Fig. 3. For each point, the nonspe-
cific binding measured in the presence of 0.25 !lM unlabeled w-CgTx 
was subtracted from total binding by 125I-Iabeled w-CgTx. The con-
centration of (±)verapamil used was 0.5 !lM. 
TABLE II 
Effect of Ca2+ channel antagonists on l'51-labeled w-conotoxin binding 
The reaction mixture contained 100 !lg of protein of chick brain 
synaptosomal preparation, various calcium antagonists as indicated 
below, and other components as stated under "Experimental Proce-
dures." In Experiment 2, all tubes contained 0.92 nM '25I-Iabeled w-
CgTx. Incubation with labeled toxin was done at room temperature 
for 1 h. 
Experiment 1 
























+ Nifedipine, 10!lM 
+ PrenylanJine lactate, 1 !lM 
+ Prenylamine lactate, 20 !lM 
+ Diltiazem, 1 !lM 
+ Diltiazem, 20 !lM 
+ Flunarizine, 1 I'M 
+ Flunarizine, 20 !lM 
+ Cinnarizine, 1 !lM 



















ing sites are distinct from each other in chick brain synapto-
somes. A number of other voltage-activated Ca2+ channel 
antagonists are known, some of which are believed to bind at 
the same site as verapamil and some (such as diltiazem) which 
have clearly different structures and pharmacological effects 
(4) and have been suggested to bind at different sites (20) . 
These antagonists were tested for their ability to inhibit 
binding by 125I-Iabeled w-conotoxin. As shown in Table II, 
none of these agents inhibit w-conotoxin binding to the high 
affinity chick brain site. 
The dihydropyridines, such as nifedipine, bind to a site 
which has been well defined by numerous studies. We tested 
whether nifedipine would influence 125I-labeled w-conotoxin 
binding; the presence of nifedipine does not detectably affect 
lUI-labeled w-conotoxin binding to chick brain synaptosomes 
(Table II). These data as well as the results in Fig. 1 lead to 
the conclusion that dihydropyridine-binding sites and the 
high affinity w-conotoxin target are distinct both in frog 
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Calcium Channel Antagonists 6233 
TABLE III 
Effect of various salts on toxin-complex formation and stability 
In Experiment 1 the reaction mixture contained 0.5 fJ.g/fJ.l protein 
of chick brain synaptosome, 0.86 nM I'6I-Iabeled w-CgTx, the salts 
given below, and other components as stated under "Experimental 
Procedures." Incubation with labeled toxin was done at room tem-
perature for 30 min. In Experiment 2, a 1.6-ml reaction mixture 
containing 2.5 fJ.g/ fJ.l protein of chick brain synaptosome, 1.3 nM 1251_ 
labeled w-CgTx and the other components of a regular binding 
medium was incubated for 30 min. This was centrifuged at 16,000 
rpm (Sorvall SS34) for 20 min, and the pellet was resuspended in 2 
ml of wash medium. After centrifugation, the washed pellet was 
resuspended in 750 fJ.I of 0.1 M sodium phosphate, pH 7.4, containing 
1 fJ.M pepstatin A, 2 fJ.M leupeptin, 1 mM 1,1O-phenanthroline, and 1 
mM phenylmethylsulfonyl fluoride. For measurement of complex 
stability, 50-fJ.I aliquots were used. The final reaction mixture (200 
fJ.1) contained 1.33 fJ.g/fJ.l protein, 75 mM sodium phosphate, pH 7.4, 
and the salts indicated below. The mixtures were filtered and washed 
after incubation at room temperature for 2 h. Standard deviations 
are shown for 3 or more independent measurements. 
Control 
+ CaCl2 (30 mM) 
+ MgCl2 (30 mM) 
+ CoCl2 (10 mM) 
+ NaCI (1 M) 
+ Cold toxin 
Experiment 1, 








Experiment 2, pre· 
formed complex 
stability after 2 h 
100 




96 ± 16 
skeletal muscle and in chick brain synaptosomes. 
These experiments suggest that w-conotoxin does not com-
pete with any of the Ca2+ channel antagonists tested and, 
therefore, defines a new site which affects voltage-activated 
Ca2+ channel activity. 
Tests for Reversibility of Binding-We have tested for the 
reversibility of binding by w-conotoxin. No significant disso-
ciation of w-conotoxin from receptor complex was found after 
2 h, even in the presence of CoCI2, CaCb, or high NaCI, even 
though these salts inhibited formation of the complex (see 
Table III). When an excess of unlabeled w-conotoxin was 
added after the complex was formed, little decrease in 1251_ 
labeled w-CgTx binding was detected. These results suggest 
that once the toxin binds its target, dissociation of the toxin 
is very slow under the conditions examined. This functional 
irreversibility makes w-conotoxin potentially more useful for 
many applications than Ca2+ channel antagonists which dis-
sociate rapidly from their targets. 
DISCUSSION 
In this report, we have demonstrated specific high affinity 
binding of w-conotoxin to synaptosomal membrane fractions 
from chick brain. The level of saturation suggests that in 
chick brain synaptosomes, the concentration of channels is 
ofthe order of 1.5 pmoljmgprotein (Fig. 3). In the microsomal 
fraction, it is :::::0.5 pmol/mg protein. 
The results suggest that the specificity of w-conotoxin is 
nonoverlapping with verapamil, diltiazem, and the dihydro-
pyridines. Dihydropyridines and w-conotoxins do not compete 
for sites in a frog muscle preparation and in a chick brain 
synaptosomal preparation. Since both dihydropyridines and 
w-conotoxins are believed to block voltage-activated calcium 
channels, these results have at least two classes of explana-
tions. It is possible that these calcium channel antagonists 
bind to different sites on the same channel, and by binding 
at different sites, are able to effect a channel block. An 
alternative explanation is that w-conotoxin and the other 
Ca2+ channel antagonists bind different types of voltage-
activated calcium channels. A combination of these hy-
potheses is of course possible. Weare presently carrying out 
a number of experiments to distinguish between these alter-
natives. 
The significance of nitrendipine-binding sites has recently 
been a subject of considerable discussion in the literature (see 
Refs. 21-23). Although it is clear that dihydropyridines can 
demonstrably block certain types of voltage-activated calcium 
channels, there is no concensus as to whether calcium chan-
nels in neuronal tissue are blocked by these agents. In frog, 
w-conotoxin GVIA has been found to block every type of 
synapse so far tested including the neuromuscular junction, a 
ganglionic synapse, and a spinal cord synapse (11).' Thus, 
differences in specificity between w-conotoxin and the dihy-
dropyridines defined by electrophysiological studies are cor-
roborated by the binding evidence presented here. 
The data in this report demonstrate that the w-conotoxin 
GVIA may define a new site which affects Ca2+ channel 
activity and will be a unique probe to explore the structure, 
function, and diversity of voltage-activated calcium channels. 
Because these peptides block synaptic transmission, w-cono-
toxins should be particularly useful for analyzing neuronal 
voltage-activated Ca2+ channels. 
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